GlycoVaxyn, GlaxoSmithKline deal

GlaxoSmithKline acquired the remaining shares of GlycoVaxyn it did not already own for $190 million, which values the company at $212 million. The deal includes a portfolio of vaccine candidates, including a Phase I candidate against Escherichia coli and a candidate against shigellosis slated to start Phase I trials in the U.S. this quarter. GSK acquired a minority stake in GlycoVaxyn in a 2012 deal that gave the pharma access to GlycoVaxyn’s bio-conjugation technology to develop new bacterial vaccines against an undisclosed set of pathogen targets (see BioCentury, Dec. 24, 2012). ...